Angiocrine Bioscience
New York
About Angiocrine Bioscience
Angiocrine Bioscience has developed a cellular platform for amplifying stem and progenitor cells, in both human and mouse models, by recapitulating the proliferative stimulation of the in vivo vascular niche in vitro. The expansion capacity is on an unprecedented scale when compared to any other competing technology, and it is achieved without the requirement for costly media additives. This process can meet the needs of a broad range of therapeutic, diagnostic, and research applications. We look forward to the expansive application of this technology to help fulfill the promise of tissue-specific engineering and organ-regeneration.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $79.2M
- Last round: Undisclosed (Sep 2025)
- Website: angiocrinebioscience.com
- Phone: 530-745-9560
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/angiocrine-bioscience-82413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.